Lipoprotein apheresis for the treatment of familial hypercholesterolemia

Clinical Lipidology

Volumn 8, Issue 5, 2013, Pages 573-586

  Walji, Shahenaz ^a   Neuwirth, Clare ^a   Thompson, Gilbert R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

heterozygote; homozygote; LDL; Lp(a); statin refractory

Indexed keywords

ATORVASTATIN; CELLULOSE; DEXTRAN SULFATE; EZETIMIBE; EZETIMIBE PLUS ROSUVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; ROSUVASTATIN; SIMVASTATIN;

ADSORPTION KINETICS; APHERESIS; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DOUBLE FILTRATION PLASMAPHERESIS; DRUG MEGADOSE; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; HEMOPERFUSION; HEPARIN EXTRACORPOREAL LOW DENSITY LIPOPROTEIN PRECIPITATION SYSTEM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HYPERLIPOPROTEINEMIA; IMMUNOADSORPTION; INTERMETHOD COMPARISON; INVESTIGATIVE PROCEDURES; LIPOPROTEIN APHERESIS; LONG TERM CARE; MEDICAL PARAMETERS; PATIENT MONITORING; PEDIGREE ANALYSIS; PLASMAPHERESIS; POSTAPHERESIS REBOUND; PRACTICE GUIDELINE; PRECIPITATION; PREGNANT WOMAN; PRIORITY JOURNAL; REVIEW; THERMOFILTRATION PLASMAPHERESIS; TREATMENT RESPONSE;

EID: 84884562385     PISSN: 17584299     EISSN: 17584302     Source Type: Journal    
DOI: 10.2217/clp.13.57     Document Type: Review

References (61)

1. Thompson GR, Lowenthal R, Myant R. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet 1, 1208-1211 (1975
2. Thompson GR, Myant NB, Kilpatrick D, Oakley CM, Raphael MJ, Steiner RE. Assessment of long-term plasma exchange for familial hypercholesterolaemia. Br. Heart J. 43, 680-688 (1980
3. Thompson GR, Miller JP, Breslow JL. Improved survival of patients with homozygous familial hypercholesterolaemia treated by plasma exchange. Br. Med. J. 291, 1671-1673 (1985
4. Stoffel W, Borberg H, Greve V. Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 2, 1005-1007 (1981
5. Thompson GR. Lipoprotein apheresis. Curr. Opin. Lipidol. 21, 487-491(2010
6. Yokoyama S, Hayashi R, Satani M, Yamamoto A. Selective removal of low density lipoprotein by plasmapheresis in familial hypercholesterolemia. Arteriosclerosis 5, 613-622 (1985
7. Mabuchi H, Michishita I, Takeda M et al. A new low density lipoprotein apheresis system using two dextran sulfate cellulose columns in an automated column regenerating unit (LDL continuous apheresis). Atherosclerosis 68, 19-26 (1987
8. Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D. Selective removal of low density lipoproteins (LDL) by precipitation at low pH; first clinical application of the HELP system. Klin. Woch. 65, 161-168 (1987
9. Klingel R, Mausfeld P, Fassbender C, Goehlen B. Lipid filtration - safe and effective methodology to perform lipid-apheresis. Transfus. Apher. Sci. 30, 245-254 (2004
10. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W. LDL hemoperfusion - a new procedure for LDL apheresis: Biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis in patients. Artif. Organs 21, 1060-1065 (1997
11. Julius U, Parhofer KG, Heibges A, Kurz S, Klingel R, Geiss HC. Dextran-sulfate-adsorption of atherosclerotic lipoproteins from whole blood or separated plasma for lipid-apheresis - comparison of performance characteristics with DALI and lipid filtration. J. Clin. Apher. 22, 215-223 (2007
12. Richter WO, Jacob BG, Ritter MM, Sühler K, Vierneisel K, Schwandt P. Three-year treatment of familial heterozygous hypercholesterolemia by extracorporeal low-density lipoprotein immunoadsorption with polyclonal apolipoprotein B antibodies. Metabolism 42, 888-894 (1993
13. Pokrovsky SN, Sussekov AV, Afanasieva OI, Adamova IY, Lyakishev AA, Kukharchuk VV. Extracorporeal immunoadsorption for the specific removal of lipoprotein(a) (Lp(a) apheresis): Preliminary clinical data. Chem. Phys. Lipids 67-68, 323-330 (1994
14. Gordon BR, Kelsey SF, Dau PC et al.; Liposorber Study Group. Long-term effects of low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. Am. J. Cardiol. 81, 407-411 (1998
15. Krebs A, Krebs K, Keller F. Retrospective comparison of 5 different methods for long-term LDL-apheresis in 20 patients between 1986 and 2001. Int. J. Artif. Organs 27, 137-148 (2004
16. Julius U, Metzler W, Pietzsch J, Fassbender T, Klingel R. Intraindividual comparison of two extracorporeal LDL apheresis methods: Lipidfiltration and HELP. Int. J. Artif. Organs 25, 1180-1188 (2002
17. Bosch T, Schmidt B, Blumenstein M, Gurland HJ. Lipid apheresis by hemoperfusion: In vitro efficacy and ex vivo biocompatibility of a new low-density lipoprotein adsorber compatible with human whole blood. Artif. Organs 17, 640-652 (1993
18. Thompson GR, HEART UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 198, 247-255 (2008
19. Richter WO, Donner MG, Schwandt P. Three low density lipoprotein apheresis techniques in treatment of patients with familial hypercholesterolemia: A long-term evaluation. Ther. Apher. 3, 203-208 (1999
20. Arends J, Bier DM, Schafer G et al. No evidence for feedback inhibition of hepatic apolipoprotein B (apoB) production after extracorporeal low density lipoprotein precipitation as determined by [1-13C] leucine infusion in normal volunteers. Eur. J. Clin. Invest. 23, 602-614 (1993
21. Thompson GR, Spinks T, Ranicar A, Myant NB. Non-steady state studies of low density-lipoprotein turnover in familial hypercholesterolaemia. Clin. Sci. Mol. Med. 52, 361-369 (1977
22. Parhofer KG, Barrett PH, Demant T, Schwandt P. Acute effects of low density lipoprotein apheresis on metabolic parameters of apoliprotein B. J. Lipid Res. 41, 1596-1603 (2000
23. Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 152, 519-526 (2000
24. Thompson GR, Barbir M, Davies D et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 208, 317-321 (2010
25. Marais AD, Naoumova RP, Firth JC, Penny C, Neuwirth CK, Thompson GR. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J. Lipid Res. 38, 2071-2078 (1997
26. Pfohl M, Naoumova RP, Klass C et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J. Lipid Res. 35, 1946-1955 (1994
27. Keller C. LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: The Munich experience. Atheroscler. Suppl. 10, 21-26 (2009
28. Raal FJ, Pilcher GJ, Panz VR et al. Reduction in mortality in subjects with homozygous familial hypercholesterolemia associated with advances in lipid-lowering therapy. Circulation 124, 2202-2207 (2011
29. Thompson GR. The evidence-base for the efficacy of lipoprotein apheresis in combating cardiovascular disease. Atheroscler. Suppl. 14(1), 67-70 (2013
30. Thompson GR, Maher VM, Matthews S et al. Familial hypercholesterolaemia regression study: A randomised trial of low-density-lipoprotein apheresis. Lancet 345, 811-816 (1995
31. Kroon AA, Aengevaeren WR, van der Werf T et al. LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis. Circulation 93, 1826-1835 (1996
32. Nishimura S, Sekiguchi M, Kano T et al. Effects of intensive lipid lowering by low-density lipoprotein apheresis on regression of coronary atherosclerosis in patients with familial hypercholesterolemia: Japan Low-density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study (L-CAPS). Atherosclerosis 144, 409-417 (1999
33. Mabuchi H, Koizumi J, Shimizu M et al. Hokuriku-FH-LDL Apheresis Study Group. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Am. J. Cardiol. 82, 1489-1495 (1998
34. Kronenberg F, Utermann G. Lipoprotein (a): Resurrected by genetics. J. Int. Med. 273, 6-30 (2013
35. Armstrong VW, Cremer P, Eberle E et al. The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis. Dependence on serum LDL levels. Atherosclerosis 62, 249-257 (1986
36. Jaeger B, Richter Y, Nagel D et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat. Clin. Pract. Cardiovasc. Med. 6, 229-239 (2009
37. Emerging Risk Factors Collaboration. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302, 412-423 (2009
38. Safarova MS, Ezhov MV, Afanasieva OI et al. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atheroscler. Suppl. 14, 93-99 (2013
39. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106, 3143-3421(2002
40. Kavey RE, Allada V, Daniels SR et al. Cardiovascular risk reduction in high-risk pediatric patients. A scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research. Circulation 114, 2710-2738 (2006
41. Sczepiorkowski ZM, Bandarenko M, Kim HC et al. Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J. Clin. Aph. 22, 106-175 (2007
42. Ito MK, McGowan MP, Moriarty PM. National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hypercholesterolemias in adult patients: Recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J. Clin. Lipidol. 5, S38-S45 (2011
43. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other societies on coronary prevention. Eur. Heart J. 19, 1434-1503 (1998
44. [Joint Federal Committee. Notice of Decision of the Federal Committee amending Directive methods contractual medical care: Apheresis with isolated Lp(a) increase for study participants]. BAnz 128, 3005 (2009
45. Civiera F. International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173, 55-68 (2004
46. Stefanutti C. The 2009 2nd Italian Consensus Conference on LDL-apheresis. Nutr. Metab. Cardiovasc. Dis. 20, 761-762 (2010
47. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein (a) as a cardiovascular risk factor: Current status. Eur. Heart J. 31, 2844-2853 (2010
48. Harada-Shiba M, Arai H, Oikawa S et al. Guidelines for the management of familial hypercholesterolemia. J. Atheroscler. Thromb. 19, 1043-1060 (2012
49. NICE. Identification and Management of Familial Hypercholesterolaemia. Clinical Guideline 71. NICE, London, UK (2008
50. Gagné C, Gaudet D, Bruckert E et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105, 2469-2475 (2002
51. Palcoux JB, Atassi-Dumont M, Lefevre P et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: Follow-up to 21 years. Ther. Apher. Dial. 12, 195-201 (2008
52. Hudgins L, Kleimann B, Scheuer A, White S, Gordon BR. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am. J. Cardiol. 102, 1199-1204 (2008
53. Kolansky DM, Cuchel M, Clark BJ et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am. J. Cardiol. 102, 1438-1443 (2008
54. Graesdal A, Bogsrud MP, Holven KB et al. Apheresis in homozygous familial hypercholesterolemia: The results of a follow-up of all Norwegian patients with homozygous familial hypercholesterolemia. J. Clin. Lipidol. 6, 331-339 (2012
55. Webb JC, Sun XM, McCarthy SM et al. Characterisation of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolaemia and frequency of these mutations in FH patients in the UK. J. Lipid Res. 37, 368-381 (1996
56. Rallides L, Naoumova RP, Thompson GR, Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 80, 583-590 (1998
57. Descamps OS, Gilbeau JP, Luwaert R, Heller FR. Impact of genetic defects on coronary atherosclerosis in patients suspected of having familial hypercholesterolaemia. Eur. J. Clin. Invest. 33, 1-9 (2003
58. Sidhu PS, Naoumova RP, Maher VM et al. The extracranial carotid artery in familial hypercholesterolaemia: Relationship of intimal-medial thickness and plaque morphology with plasma lipids and coronary heart disease. J. Cardiovasc. Risk 3, 61-67 (1996
59. Thompson GR. LDL apheresis. Atherosclerosis 167, 1-13 (2003
60. Berthold HK, Descamps OS, Gouni-Berthold I. Lipoprotein apheresis in isolated hyperlipoproteinemia(a): A validated treatment or an illusion of validity?. Eur. J. Clin. Invest. 43, 108-112 (2013
61. Cuchel M, Meagher EA, du Toit Theron H et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, Phase 3 study. Lancet 381, 40-46 (2013